Medication Safety During Polypharmacy Transitions

Abstract

Medication safety is a critical concern during polypharmacy transitions, particularly among vulnerable populations such as older adults and patients with complex comorbidities. This review synthesizes current evidence on the epidemiology, pathophysiology, risk factors, clinical features, diagnostic methods, management strategies, recent advances, and guideline recommendations related to medication safety in polypharmacy transitions. Emphasis is placed on mechanisms of iatrogenic harm, practical risk mitigation, and the clinical implications of recent research, aiming to provide healthcare professionals with an up-to-date, comprehensive perspective for optimizing patient outcomes during medication regimen changes.

Introduction

Polypharmacy, typically defined as the concurrent use of five or more medications, is increasingly prevalent due to aging populations and the rising burden of chronic diseases. Transitions in care, such as hospital admission, discharge, or transfer between healthcare settings, are periods of heightened vulnerability for adverse drug events (ADEs) and medication errors. Ensuring medication safety during these transitions is paramount, as mismanagement can result in significant morbidity, hospital readmissions, and even mortality. This article reviews the multifaceted aspects of medication safety during polypharmacy transitions, integrating recent guideline updates, evidence-based risk mitigation strategies, and clinical best practices.

Epidemiology / Disease Burden

The prevalence of polypharmacy in older adults ranges from 40% to 60% in developed countries, with up to 20% experiencing potentially inappropriate medication use. Transitions of care are associated with a 30–50% increase in risk for medication discrepancies, and ADEs account for 15–20% of hospital readmissions in the elderly. The burden is compounded by demographic trends, multimorbidity, and fragmented healthcare delivery, underscoring the necessity for robust medication safety strategies during transitions.

Pathophysiology

The pathophysiology underlying medication-related harm during polypharmacy transitions involves complex pharmacokinetic and pharmacodynamic interactions. Altered drug absorption, distribution, metabolism, and excretion exacerbated by age-related physiological changes and comorbidities heighten the risk for toxicity or therapeutic failure. Polypharmacy increases the probability of drug-drug and drug-disease interactions, while abrupt regimen changes can destabilize chronic disease control, precipitating adverse clinical outcomes.

Risk Factors

Key risk factors for medication errors during polypharmacy transitions include advanced age, cognitive impairment, renal or hepatic dysfunction, polypharmacy itself, use of high-risk medications (e.g., anticoagulants, hypoglycemics), communication barriers, inadequate medication reconciliation, and lack of standardized transition protocols. Social determinants, such as health literacy and support systems, further modulate risk profiles, necessitating individualized assessment during care transitions.

Clinical Features

Clinical manifestations of medication-related harm are highly variable and may be nonspecific, particularly in the elderly. Presentations can include delirium, falls, bleeding, renal dysfunction, hypoglycemia, or exacerbation of underlying diseases. Polypharmacy transitions may unmask latent side effects, provoke withdrawal syndromes, or trigger therapeutic duplications and omissions, challenging clinicians to differentiate iatrogenic events from disease progression.

Diagnosis

Diagnosis of medication-related complications during polypharmacy transitions relies on a high index of suspicion, thorough medication history, and systematic use of tools such as the Medication Appropriateness Index, Beers Criteria, and STOPP/START criteria. Medication reconciliation at each transition point is essential, involving verification of current medications, assessment of indication, dose, route, and identification of potential interactions or duplications. Clinical pharmacists play a pivotal role in this diagnostic process.

Treatment & Management

Optimizing medication safety during polypharmacy transitions necessitates a multidisciplinary approach. Key strategies include comprehensive medication reconciliation, deprescribing of unnecessary or high-risk medications, clear communication among healthcare providers, patient and caregiver education, and use of clinical decision support systems. Tailoring therapy to individual risk factors such as renal function or cognitive status further mitigates harm. Post-discharge follow-up and close monitoring for ADEs are critical components of effective management.

Recent Advances / Emerging Therapies

Recent advances in medication safety during polypharmacy transitions include the integration of electronic health records (EHRs) with clinical decision support tools, development of algorithm-based deprescribing protocols, and implementation of pharmacist-led transition-of-care interventions. Artificial intelligence (AI) models are being developed to predict high-risk transitions and flag potential drug interactions in real time. Telemedicine follow-up and remote monitoring technologies also show promise in supporting safe medication transitions post-discharge.

Guideline Recommendations

Major guidelines from organizations such as the American Geriatrics Society and WHO emphasize systematic medication reconciliation at every care transition, regular review of medication regimens using validated tools, and prioritization of shared decision-making with patients. Deprescribing, when appropriate, should be guided by established protocols, with ongoing risk-benefit assessment. Guidelines advocate for the involvement of clinical pharmacists and highlight the importance of structured communication handoffs and patient education to reduce avoidable harm.

Conclusion

Medication safety during polypharmacy transitions remains a complex, multifactorial challenge with significant clinical implications. Effective risk mitigation relies on robust medication reconciliation, interdisciplinary collaboration, evidence-based deprescribing, and patient-centered care. Recent technological and procedural advances offer opportunities to further reduce medication-related harm. Continued vigilance, education, and adherence to guideline-based practices are essential for optimizing outcomes and safeguarding patient safety during transitions in care.